Gilead Sciences, a prominent player in the pharmaceutical industry, experienced a significant blow on Monday as shares of the company plummeted by over 10%. This dramatic decrease in stock value came on the heels of disappointing results from a late-stage trial involving one of Gilead’s best-selling cancer drugs, Trodelvy. The trial revealed that Trodelvy did
0 Comments